ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 1066 • ACR Convergence 2023

    Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples

    Kelly Chun and Jane Yang, Labcorp, Calabasas, CA

    Background/Purpose: Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment. In suboptimal response, drug and anti-drug antibody…
  • Abstract Number: 1791 • ACR Convergence 2023

    Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622

    James Sullivan1, Vandana Rai2, Jennifer Harvey2, Vincent Del Signore2, Unnikrishnan Chandrasekharan2 and M. Elaine Husni3, 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH

    Background/Purpose: Despite the widespread use of anti-TNFα therapy in psoriatic arthritis (PsA), a significant proportion of patients fail to achieve a complete treatment response. There…
  • Abstract Number: 0450 • ACR Convergence 2023

    Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

    Martinus Van de Laar1, Martijn Oude Voshaar1, Peter ten Klooster1, Danyta Tedjo2 and celine van de laar3, 1University of Twente, Hengelo (OV), Netherlands, 2TiH @ University of Twente, Hengelo (OV), Netherlands, 3Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands

    Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
  • Abstract Number: 1080 • ACR Convergence 2023

    Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study

    Antoine Minier1, Gilles Boire1, Sophie ROUX1, Nathalie Carrier2 and Hugues Allard-Chamard1, 1Université de Sherbrooke, Sherbrooke, QC, Canada, 2CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada

    Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE)…
  • Abstract Number: 1937 • ACR Convergence 2023

    Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis

    Frank Cai1, Anisha Paulson1, Amy Wozniak2, Emily Gilbert2 and Rochella Ostrowski2, 1Loyola University Medical Center, Oak Park, IL, 2Loyola University Medical Center, Maywood, IL

    Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
  • Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium

    Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy

    Claire Yang1, Natalie Rosenwasser2, Xing Wang2, Zheng Xu2, Joshua Scheck2, Ramesh Iyer3 and Yongdong (Dan) Zhao3, 1University of Washington School of Medicine, Seattle, WA, 2Seattle Children's Hospital, seattle, WA, 3University of Washington, Seattle, WA

    Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
  • Abstract Number: 096 • 2023 Pediatric Rheumatology Symposium

    DADA2 – a Case Series from North India

    Manjari Agarwal, Jyotsna verma, ratna puri and Sujata Sawhney, Sir Ganga Ram Hospital, New Delhi, India

    Background/Purpose: We present a series of children previously diagnosed and managed as Polyarteritis nodosa at our unit. Due to ease of availability of mutation analysis…
  • Abstract Number: 0143 • ACR Convergence 2022

    National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol

    José Luis Martín-Varillas1, Lara Sánchez-Bilbao2, Vanesa Calvo Río3, Alf Adán4, Inés Hernanz Rodríguez4, Emma Beltrán Catalán5, Sonia Castro Oreiro6, Patricia Fanlo7, Alvaro Garcia8, Ignacio Torre9, Miguel Cordero Coma10, Juan Ramón de Dios11, A. Garcia-Aparicio12, Marisa Hernandez Garfella13, Amalia Sánchez Andrade14, A. García-valle15, Olga Maiz16, Juan Roberto Miguelez Sanchez12, Sergio Rodriguez Montero17, Ana Urruticoechea18, Raul Veroz19, Arantxa Conesa20, Cristina Fernández-Carballido21, Vega Jovani Casano22, Olga Martinez23, Patricia Moya Alvarado24, Susana Romero Yuste25, Paula Rubio Muñoz26, eva Peña Sainz-Pardo27, Marta Garijo Bufort28, José Luis Hernández2 and Ricardo Blanco29, 1Hospital de Laredo, Laredo, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4H. Clinic, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain, 6H. Universitario Joan XXIII, Barcelona, Spain, 7Complejo Hospitalario de Navarra, Navarra, Spain, 8Hospital Tajo, Madrid, Spain, 9Hospital de Basurto, Basurto, Spain, 10Hospital de León, León, Spain, 11Hospital de Araba, Araba, Spain, 12Hospital Universitario de Toledo, Toledo, Spain, 13Hospital Universitario General de Valencia, València, Spain, 14Hospital Universitario Lucus Augusti, Lugo, Spain, 15Completo Asistencial Palencia, Palencia, Spain, 16Hospital Universitario de Donostia, San Sebastián, Spain, 17Virgen de Valme University Hospital, Sevilla, Spain, 18Hospital Can Misses, Ibiza, Spain, 19Hospital de Mérida, Mérida, Spain, 20Hospital Universitario de Castellón, València, Spain, 21Agencia Valenciana de Salud, Alicante, Spain, 22National Health system, Alicante, Spain, 23Hospital Clínico Universitario de Salamanca, Zamora, Spain, 24Hospital Parc Tauli, Barcelona, Spain, 25Complexo Hospitalario Universitario, Pontevedra, Spain, 26H. Esperit Sant, Barcelona, Spain, 27Hospital Universitario 12 de Octubre, Madrid, Spain, 28Hospital Sagunto, València, Spain, 29Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of noninfectious uveitis. There are few reports on the effectiveness…
  • Abstract Number: 0778 • ACR Convergence 2022

    TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases

    Ulf Geisen1, Ruben Rose2, Dennis Berner3, Hayley Reid3, Jan Schirmer4, Florian Tran5, Sascha Gerdes6, Stefan Schreiber7, Andi Krumbholz1, Petra Bacher7 and Bimba Hoyer1, 1UKSH Kiel, Kiel, Germany, 2Dep Infectiology UKSH Kiel, Kiel, Germany, 3Dep Rheumatology and clinical Immunology, UKSH Kiel, Kiel, Germany, 4University Medical Center Schleswig-Holstein, Kiel, Germany, 5Medical Department, UKSH Kiel, Kiel, Germany, 6Dermatology, UKSH Kiel, Kiel, Germany, 7Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany

    Background/Purpose: Background: The ongoing pandemic is an immunological challenge when using immune modulating drugs. The mRNA vaccines against SARS-CoV-2 are safe and efficient in most…
  • Abstract Number: 1556 • ACR Convergence 2022

    Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

    Alba Herrero-Morant1, José Luis Martín-Varillas2, Santos Castañeda3, Olga Maiz4, Julio Sánchez-Martín5, Norberto Ortego6, Enrique Raya7, Águeda Prior-Español8, Clara Moriano9, Rafael Melero10, Genaro Graña-Gil11, Ana Urruticoechea12, Angel Ramos13, Marta Loredo-Martínez14, Eva Salgado-Pérez15, Francisca Sivera16, Ignacio Torre17, F. Javier Narváez18, Jose Luis Andreu19, Olga Martinez20, Ricardo Gómez-de la Torre21, Sabela Fernandez-Aguado22, Susana Romero Yuste23, iñigo Gonzalez-Mazon5, Carmen Alvarez Reguera5, David Martínez-López5, José Luis Hernández5, Miguel Ángel González-Gay24 and Ricardo Blanco25, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital de Laredo, Laredo, Cantabria, Spain, 3Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 4Hospital Universitario de Donostia, San Sebastián, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Medicine Department, Universidad de Granada, Granada, Spain, 7Hospital San Cecilio, Granada, Spain, 8Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 9Complejo Asistencial Universitario de León, León, Spain, 10Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 11Hospital Universitario de A Coruña, A Coruña, Spain, 12Hospital Can Misses, Ibiza, Spain, 13Complejo Hospitalario de Soria, Soria, Spain, 14Hospital Clínico Lozano Blesa, Zaragoza, Spain, 15Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, 16Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 17Hospital de Basurto, Basurto, Spain, 18Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 20Hospital Clínico Universitario de Salamanca, Zamora, Spain, 21Hospital Universitario Central de Asturias, Oviedo, Spain, 22Hospital Universitario de Cabueñes, Gijon, Spain, 23Complexo Hospitalario Universitario, Pontevedra, Spain, 24Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 25Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
  • Abstract Number: 2150 • ACR Convergence 2022

    Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

    Federica Lumetti1, Alarico Ariani2, Camilla Coccolini3, Carlo Salvarani4 and Gilda Sandri4, 1Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, 2Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, 3Università di Modena e Reggio Emilia, Modena, Italy, 4Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy

    Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
  • Abstract Number: 0283 • ACR Convergence 2022

    The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)

    Nobuyuki Yajima1, Toshihiro Matsui2 and Shigeto Tohma3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2NHO Sagamihara National Hospital, Kanagawa, Japan, 3National Hospital Organization Tokyo National Hospital, Dallas, TX

    Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
  • Abstract Number: 0796 • ACR Convergence 2022

    SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?

    Carla Goncalves Schahin Saad1, Matheus SR Silva2, PERCIVAL SAMPAIO-BARROS1, Julio Moraes3, Claudia G Schainberg2, Celio Roberto goncalves1, Andrea Shimabuco1, Nadia Aikawa1, Emily Figueiredo Neves Yuki1, Sandra Gofinet Pasoto4, Leonard VK Kupa2, Renato K Aoyama2, Carlo Araujo1, Clovis A. Silva5, ana Medeiros6 and Eloisa Silva Dutra de Oliveira Bonfa4, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, São Paulo, 3Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil

    Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
  • Abstract Number: 1564 • ACR Convergence 2022

    Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease

    Nuria Barroso-García1, Belén Atienza-Mateo2, Ivan Ferraz Amaro3, Diana Prieto-Peña2, Ana De Vicente-Delmás4, Ricardo Blanco5 and Miguel Ángel González-Gay6, 1Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 4Hospital General Santa María del Puerto, Cádiz, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
  • Abstract Number: 2199 • ACR Convergence 2022

    Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

    Jeffrey Curtis1, Yujie Su2, Cassie Clinton2, Patrick Stewart3, Bryant England4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Bendcare, Boca Raton, FL, 4University of Nebraska Medical Center, Omaha, NE, 5FASTER, Hoover, AL

    Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology